TechCrunch · Dec 17, 2019
TechCrunch reports OM1’s patient-record analytics expansion
Markdown · JSON · Original source
TechCrunch’s report, published December 17, 2019, says OM1 raised $50 million to expand sales, marketing and product development. The company offered hospitals and pharmaceutical companies clinical insights drawn from patient records. The report describes possible uses: pharmaceutical companies could use data in discussions with the Food and Drug Administration, while hospitals and physicians could compare outcomes from different courses of care. OM1 CEO and founder Dr. Richard Gliklich said the funding would accelerate the company’s work on access to real-world outcomes and evidence. The report does not provide results showing that OM1’s data improved care or reduced costs.
Headline and summary by Escape Meridian, prepared by Luna from the attributed source. A source check is not independent confirmation of the source’s claims.
Original source
TechCrunch · Article
Source details
Original source date: Dec 17, 2019 (2019-12-17).
Date basis: Date from the publisher’s archive: its article address or archive listing.
Added to Escape Meridian: 2026-10-29T00:42:39.242Z. First observed: 2026-10-25T15:15:46.275Z. Retrieved: 2026-10-25T15:17:56.947Z.
Referenced by
Recorded citations and public file attachments. A reference alone does not establish agreement or influence.
No public references recorded here yet.
Limits
Text as retrieved on October 25, 2026; originally published December 17, 2019. The report describes intended uses of OM1’s data but provides no results showing that the data improved treatment or lowered costs.
Open question
What evidence, if any, would show that OM1’s data improved treatment or reduced healthcare costs?
Source-stated
OM1 raised $50 million to expand sales and marketing and product development.
has raised $50 million in its latest round of financing to expand its sales and marketing and product development activities
Source-stated
The report says pharmaceutical companies could use data in interactions with the Food and Drug Administration, while hospitals and physicians could use it to assess outcomes from different courses of care.
Pharmaceutical companies can use the data in their interactions with the Food and Drug Administration to make a case for the utility of certain drugs, while hospitals and physicians use the data to improve treatment by looking at which courses of care produced the best outcomes.
Source-stated
Gliklich said the funding would accelerate OM1’s work toward providing access to real-world outcomes and evidence.
With this funding, OM1 will accelerate our work towards delivering rapid access to real-world outcomes and evidence
Source and contributor context
TechCrunch · Publisher
The publisher is identified here. No individual author has been inferred.
Source media
Media retrieval status: unchecked.
Terms and references
Reference context selected by Escape Meridian; separate from source evidence. Entity mentions do not establish authorship, involvement or endorsement.
Editorial provenance
Version 1. Publication ID: 391f3050-892b-2cd5-47d3-658d25e274d0.
Prepared by openai/gpt-6-luna; grounding review by anthropic/claude-opus-5.5.
Source check: passed by anthropic/claude-opus-5.5 on 2026-10-29T00:41:27.418Z. This checks fidelity to the source, not whether its claims are independently true.
Editorial selection: accept; reasons: bridge_admitted_by_model.
Observation: bdaa2f81524a8612c1c7b7ded67ff6633a476fc831c66a928e72ac3fecb527b2. Source text hash: d9ff1d07c6814ead1ccf8af0999782daa38aef3073314502f78618dcfee8c1ad.
Revision and source-check history
Version 1 · 2026-10-29T00:42:39.242Z
TechCrunch reports OM1’s patient-record analytics expansion
TechCrunch’s report, published December 17, 2019, says OM1 raised $50 million to expand sales, marketing and product development. The company offered hospitals and pharmaceutical companies clinical insights drawn from patient records. The report describes possible uses: pharmaceutical companies could use data in discussions with the Food and Drug Administration, while hospitals and physicians could compare outcomes from different courses of care. OM1 CEO and founder Dr. Richard Gliklich said the funding would accelerate the company’s work on access to real-world outcomes and evidence. The report does not provide results showing that OM1’s data improved care or reduced costs.
Original source
TechCrunch · Article
Source details
Original source date: Dec 17, 2019 (2019-12-17).
Date basis: Date from the publisher’s archive: its article address or archive listing.
Added to Escape Meridian: 2026-10-29T00:42:39.242Z. First observed: 2026-10-25T15:15:46.275Z. Retrieved: 2026-10-25T15:17:56.947Z.
Limits
Text as retrieved on October 25, 2026; originally published December 17, 2019. The report describes intended uses of OM1’s data but provides no results showing that the data improved treatment or lowered costs.
Open question
What evidence, if any, would show that OM1’s data improved treatment or reduced healthcare costs?
Source-stated
OM1 raised $50 million to expand sales and marketing and product development.
has raised $50 million in its latest round of financing to expand its sales and marketing and product development activities
Source-stated
The report says pharmaceutical companies could use data in interactions with the Food and Drug Administration, while hospitals and physicians could use it to assess outcomes from different courses of care.
Pharmaceutical companies can use the data in their interactions with the Food and Drug Administration to make a case for the utility of certain drugs, while hospitals and physicians use the data to improve treatment by looking at which courses of care produced the best outcomes.
Source-stated
Gliklich said the funding would accelerate OM1’s work toward providing access to real-world outcomes and evidence.
With this funding, OM1 will accelerate our work towards delivering rapid access to real-world outcomes and evidence
Source and contributor context
TechCrunch · Publisher
The publisher is identified here. No individual author has been inferred.
Source media
Media retrieval status: unchecked.
Terms and references
Reference context selected by Escape Meridian; separate from source evidence. Entity mentions do not establish authorship, involvement or endorsement.
Editorial provenance
Version 1. Publication ID: 391f3050-892b-2cd5-47d3-658d25e274d0.
Prepared by openai/gpt-6-luna; grounding review by anthropic/claude-opus-5.5.
Source check: passed by anthropic/claude-opus-5.5 on 2026-10-29T00:41:27.418Z. This checks fidelity to the source, not whether its claims are independently true.
Editorial selection: accept; reasons: bridge_admitted_by_model.
Observation: bdaa2f81524a8612c1c7b7ded67ff6633a476fc831c66a928e72ac3fecb527b2. Source text hash: d9ff1d07c6814ead1ccf8af0999782daa38aef3073314502f78618dcfee8c1ad.
passed · 2026-10-29T00:41:27.418Z · anthropic/claude-opus-5.5
Publication: 391f3050-892b-2cd5-47d3-658d25e274d0
attribution — pass: The reading attributes the report to TechCrunch and the quoted statement to OM1 CEO and founder Dr. Richard Gliklich, both matching the source text.
said Dr. Richard Gliklich, CEO and founder of OM1
summary — pass: The summary identifies the actor (OM1), the development (a $50 million raise for sales, marketing and product development) and the uses the report describes. It notes that no outcome results are given. The language is plain enough for non-specialists. The question addresses a genuine unresolved issue rather than posing a leading claim.
brings clinical insights to hospitals and big pharma companies alike
date — pass: December 17, 2019 matches originalPublished at day precision. The Most Popular sidebar describes later stories, but the reading does not use or rely on them. The evidence kind is publisher-page, so no archive disclosure is required. Past-tense framing avoids hindsight.
support — pass: Each claim is directly supported by an exact source excerpt. The reading frames the FDA and treatment uses as possibilities described by the report, not demonstrated benefits. Its limitation that no results are shown is consistent with the text. It adds no unsupported benefits or costs.
Pharmaceutical companies can use the data in their interactions with the Food and Drug Administration to make a case for the utility of certain drugs
media — pass: No media candidates were supplied and none was selected, which is appropriate.
Challenge or correct this reading
Send a correction or an opposing source with this reading’s URL. Disagreement and uncertainty can remain unresolved.